Background and Aim: Liver Cirrhosis patients are more prone to lower gastrointestinal (GI) bleeding hypothetically caused by portal hypertensive colopathy (PHC) and anorectal varices (ARVs). The present study aimed to determine the incidence of colopathic lesions and investigate their association with cirrhosis severity and portal hypertensive colopathy manifestation. Patients and Methods: This cross-sectional study was carried out on 80 liver cirrhosis patients in the Department of Gastrointestinal, CMH Hospital Lahore from January 2021 to December 2022. Individuals aged >18 years with liver cirrhosis were enrolled. Each individual underwent laboratory, clinical, and ultrasonographic examinations. Upper gastrointestinal endoscopy was used to detect the PHC. Based on the colopathic lesions severity, patients were categorized into three grades: grade I (colonic mucosa), grade II (mucosa with mosaic-like pattern), and grade III (angiodysplasia-like colon lesions). SPSS version 27 was used for data analysis. Results: The overall mean age was 48.62±5.6 years with an age range 19 to 70 years. Of the total patients, there were 60 (75%) male and 20 (25%) females. Child-Pugh classification of patients were as follows: Class A 16 (20%), Class B 29 (36.3%), and Class C 35 (43.7%).

Background and Aim: One of the most common and obvious signs of liver cirrhosis is fatigue, which can limit daily activities, minimizes physical activity. Fatigue was reported to be prevalent in 60-80% of cirrhotic individuals in early publications on the clinical profile. The purpose of the current study was to evaluate the prevalence and etiology of fatigue in chronic liver disease. Patients and Methods: This cross-sectional study was carried out on 320 chronic liver disease patients in Department of Medicine PAF Hospital Lahore and Department of Gastroenterology CMH Lahore from June 2022 to December 2022. Study protocol was approved by institute ethical committee. We recruited (a) those who had ongoing liver disease caused by HCV or HBV, (b) patients between the ages of 16 and 70, and (c) patients who had not previously received any particular HCV or HBV therapy. Patients were divided into five groups: Group-I comprised of chronic hepatitis patients, Group-II had Child class A Cirrhosis, Group-III had Child class B cirrhosis, Group-IV had Child class C cirrhosis, and Group-V had hepatocellular carcinoma (HCC) patients. Patients were subjected to abdominal ultrasonography, laboratory investigations, and upper endoscopy.